Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

282.20 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
The Week Ahead: PCE Inflation Data And Big Tech Earnings In Focus
Markets brace for crucial week with Big Tech earnings, Trump's 100-day milestone, and key economic data as trade concerns linger. 
Via Talk Markets
Topics Economy Government Stocks / Equities
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Economy Intellectual Property World Trade
1 Value Stock to Research Further and 2 to Ignore
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are... 
Via StockStory
Is the Market Bullish or Bearish on Amgen?
 
Via Benzinga
P/E Ratio Insights for Amgen
 
Via Benzinga
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Amgen, Franco-Nevada, Take-Two Interactive And More: CNBC's 'Final Trades'
 
Via Benzinga
Short Week Finishes With Netflix Q1 Beat
Considering the blue-chip Dow face-planted ahead of the open on a disappointing Q1 report from UnitedHealth, which resulted in a -22% tanking by Thursday’s close, this was a pretty flat day. 
Via Talk Markets
Topics Stocks Stocks / Equities
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035. 
Via Benzinga
2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever
Via The Motley Fool
Topics Government World Trade
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with AbbVie... 
Via StockStory
Topics Artificial Intelligence
Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the inflammatory disease market. 
Via Benzinga
Topics Intellectual Property Lawsuit
Sandoz Files Antitrust Lawsuit Against Amgen Over Inflammation Drug, Seeks Damages: Retail Sentiment Falters
Sandoz is seeking an injunction to prevent Amgen from using patent rights to block biosimilar competition and allow Sandoz to launch its Erelzi “as soon as possible.” 
Via Stocktwits
Topics Government Intellectual Property Lawsuit
Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury
The company is continuing to test a daily pill that blocks GIPR. 
Via Investor's Business Daily
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs. 
Via Benzinga
Topics Government World Trade
S&P, Dow Jones Pharma Names Rattled — Again — On Trump's Tariffs Whiplash
Here's why the 90-day tariffs delay doesn't help pharmaceutical companies. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Rule Breaker Investing: Essays From Yesterday, Vol. 7
Via The Motley Fool
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
The US market session of Wednesday has yet to be opened, let's have a look at the top S&P500 gainers and losers in the pre-market session today. 
Via Chartmill
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Trump Hints At 'Major Tariff' On Imported Pharmaceuticals: Pfizer, Eli Lilly, Amgen And Other Stocks Tumble In Wednesday Pre-Market
President Donald Trump has declared that his administration is on the brink of imposing a significant tariff on pharmaceuticals imported from foreign countries. 
Via Benzinga
Topics Government World Trade
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
Topics Economy Intellectual Property
2 Dividend Stocks to Buy Hand Over Fist in April
Via The Motley Fool
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies. 
Via Benzinga
Topics Government World Trade
Nasdaq 100 Enters Bear Market, Dow In Correction Territory, Traders Await Fed Chair Powell's Remarks
Dip-buying absent in early NY trading, Wall Street deep in red as trade war fears escalate despite strong jobs report. Investors on edge for hints from Fed Chair Powell. 
Via Benzinga
Topics Economy Stocks World Trade
FDA Approves Amgen's Uplizna As First Drug For Chronic Immune-Mediated Fibroinflammatory Disorder
The FDA approved Amgen's Uplizna as the first treatment for IgG4-RD. The decision is backed by the MITIGATE trial, showing reduced flares and sustained efficacy. 
Via Benzinga
Amgen Stock Edges Higher After Uplizna Becomes First FDA-Approved Treatment For Immune-Mediated Disorder – Retail Gets More Bullish
Uplizna is now the first FDA-approved treatment for Immunoglobulin G4-related disease, affecting an estimated 20,000 people in the United States 
Via Stocktwits
Topics Government World Trade
Amgen, Sabra Health Care And A Financial Stock On CNBC's 'Final Trades'
 
Via Benzinga
Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday
Via The Motley Fool
Topics Economy Government World Trade
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
57 58 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS